Skip to content

Doripenem

    Brands

    DEA Class; Rx

    Common Brand Names; Doribax

    • Carbapenems

    IV broad spectrum carbapenem antibiotic
    For complicated intraabdominal and urinary tract infections in adults
    Spectrum of activity similar to imipenem and meropenem but is more active in vitro against Pseudomonas aeruginosa

    Indicated for the treatment of complicated intraabdominal infections.

    For the treatment of complicated urinary tract infection (UTI), including pyelonephritis, and in patients with concurrent bacteremia.
    For the treatment of sepsis.

    Hypersensitivity to doripenem, beta-lactams or similar drugs

    • Headache (4-16%)
    • Nausea (4-12%)
    • Diarrhea (6-11%)
    • Anemia (2-10%)
    • Phlebitis (4-8%)
    • Rash (1-5%)
    • Pruritus (3%)
    • Transaminases elevated (1-2%)
    • Oral candidiasis (1%)
    • Renal impairment/failure (1%)
    • Anaphylaxis
    • Leukopenia
    • Neutropenia
    • Seizure
    • Thrombocytopenia
    • Toxic epidermal necrolysis, Stevens-Johnson Syndrome
    • Interstitial pneumonia
    • Renal impairment/failure

    History of sensitivity to multiple allergens

    May reduce serum valproic acid conc to subtherapeutic level: monitor levels frequently

    Risk of Clostridium difficile-associated diarrhea on long-term use

    Seizures reported with use

    Not approved for ventilator-associated bacterial pneumonia (or any type of pneumonia); increased mortality when compared with imipenem/cilastatin (23% vs 16.7%); additionally, clinical response rates were lower with doripenem

    Pregnancy Category: B

    Lactation: unknown if excreted in breast milk; use caution

    Adults

    500 mg IV every 8 hours.

    Elderly

    500 mg IV every 8 hours.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Doripenem

    powder for injection

    • 500mg/vial